FI112942B - Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenyl-derivat - Google Patents

Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenyl-derivat Download PDF

Info

Publication number
FI112942B
FI112942B FI920749A FI920749A FI112942B FI 112942 B FI112942 B FI 112942B FI 920749 A FI920749 A FI 920749A FI 920749 A FI920749 A FI 920749A FI 112942 B FI112942 B FI 112942B
Authority
FI
Finland
Prior art keywords
group
methyl
reaction
singlet
triplet
Prior art date
Application number
FI920749A
Other languages
English (en)
Finnish (fi)
Other versions
FI112942B3 (sv
FI920749A (fi
FI920749A0 (fi
Inventor
Hiroyuki Koike
Koichi Fujimoto
Hiroaki Yanagisawa
Takuro Kanazaki
Yoshiya Amemiya
Yasuo Shimoji
Toshio Sada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112942(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of FI920749A0 publication Critical patent/FI920749A0/fi
Publication of FI920749A publication Critical patent/FI920749A/fi
Priority to FI955248A priority Critical patent/FI112941B/sv
Publication of FI112942B publication Critical patent/FI112942B/sv
Application granted granted Critical
Publication of FI112942B3 publication Critical patent/FI112942B3/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Phenolic Resins Or Amino Resins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Claims (3)

1. R2 r^\Lr* OR* CH2 R5 γΊι I ω fjLRr o 5 i vilken formeln R1 avser en propylgrupp;
10 R2 och R3 vardera avser en metylgrupp; R4 avser en väteatom; R5 avser en karboxigrupp eller en grupp med formeln -COOR5a, 15 där R5a avser en (5-metyl-2-oxo-l,3-dioxolen-4-yl)metylgrupp; R7 avser en tetrazol-5-ylgrupp vid 2-positionen av benzenringen; och farmaceutiskt acceptabela salter av detta, 285 kännetecknat därav,attförfarandetinnefattarföljandesteg: man läter en förening med formeln (II): Rl-^N-V/Rd H R 5 där: R1 är definierad som ovan och Rd avser en grupp med formeln f -C—R3 OR4 Λ i Λ 10 där R , R och R är definierade som ovan, A f f eller R avser en grupp med formeln -COOR, där R avser en karboxi-skyddande grupp, eller Rd avser en grupp med formeln -COR2, där R2 är definierad som ovan eller Rd avser en cyanogrupp; och 15 Re avser en cyanogrupp, en karboxigrupp eller en grupp med formeln -COORf, där Rf är definierad som ovan, reagera med en förening med formeln (III): X 286 CH, Λ (HI) fit „ där R7a avser en skyddad karboxigrupp, en cyanogrupp, en skyddad tetrazol-5-ylgrupp, en karbamoylgrupp eller en alkylkarbamoylgrupp; och X avser en halo-genatom; 5 for att fa en forening med formeln (IV): .N. a* |V Λ „ ö‘" där Rd, Re, R1 och R7a är definierade som ovan; och 287 i vilken ordning som heist avlägsnas skyddande grupper och vid behov omvandlas nämnda grupp Rd till en grupp med formeln f -C—R3 OR1 där R , R och R är definierade som ovan, 5 och vid behov omvandlas nämnda Re till en grupp R2 eller omvandlas nämnda 7n 7 grupp R till en grupp R for att fa en forening med formeln (I); och valbart bildas produktens salt. 10
1. Förfarande för framställning av för behandling och förebyggande av höjt blod-tryck användbar4'-(lH-imidazol-l-ylmetyl)-l,r-bifenylderivat med formeln (I),
2. Förfarande enligt patentkrav 1, kännetecknat därav, att framställas en forening, där R2 är en grupp med formeln -COOR5a där R5a avser en (5-metyl-2-oxo-1,3 -dioxolen-4-yl)metylgrupp. 15
3. Förfarande enligt patentkrav 1, kännetecknat därav, att föreningen for att framställas är 4-(l-hydroxi-l-metyletyl)-2-propyl-l-{4-[2-(tetrazol-5- yl)fenyl]fenyl}metylimidazol-5-karboxylsyra. Förfarande enligt patentkrav 1, kännetecknat därav, att föreningen for 20 att framställas är (5-metyl-2-oxo-l,3-dioxolen-4-yl)metyl-4-(l-hydroxi-l- 2 metyletyl)-2-propyl-l-{4-[2-(tetrazol-5-yl)fenyl]fenyl}metylimidazol-5-karboxylat.
FI920749A 1991-02-21 1992-02-20 Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenyl-derivat FI112942B3 (sv)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI955248A FI112941B (sv) 1991-02-21 1995-11-02 Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenylderivat

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP2709891 1991-02-21
JP9658891 1991-04-26
JP9658891 1991-04-26
JP13488991 1991-06-06
JP13488991 1991-06-06
JP16713891 1991-07-08
JP16713891 1991-07-08
JP17397291 1991-07-15
JP17397291 1991-07-15
JP18484191 1991-07-24
JP18484191 1991-07-24

Publications (4)

Publication Number Publication Date
FI920749A0 FI920749A0 (fi) 1992-02-20
FI920749A FI920749A (fi) 1992-08-22
FI112942B true FI112942B (sv) 2004-02-13
FI112942B3 FI112942B3 (sv) 2012-03-13

Family

ID=27549327

Family Applications (2)

Application Number Title Priority Date Filing Date
FI920749A FI112942B3 (sv) 1991-02-21 1992-02-20 Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenyl-derivat
FI955248A FI112941B (sv) 1991-02-21 1995-11-02 Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenylderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI955248A FI112941B (sv) 1991-02-21 1995-11-02 Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenylderivat

Country Status (23)

Country Link
EP (2) EP0503785B3 (sv)
JP (1) JPH07121918B2 (sv)
KR (1) KR0128289B1 (sv)
CN (3) CN1045770C (sv)
AT (2) ATE200777T1 (sv)
CA (2) CA2229000C (sv)
CZ (1) CZ289194B6 (sv)
DE (6) DE122009000024I1 (sv)
DK (2) DK0545912T3 (sv)
ES (2) ES2156866T3 (sv)
FI (2) FI112942B3 (sv)
GR (2) GR3035909T3 (sv)
HK (2) HK1011361A1 (sv)
HU (3) HU223338B1 (sv)
IE (1) IE920540A1 (sv)
IL (3) IL114996A (sv)
IS (1) IS1756B (sv)
LU (4) LU91056I2 (sv)
NL (3) NL300133I2 (sv)
NO (6) NO304516B3 (sv)
NZ (1) NZ241681A (sv)
PT (2) PT503785E (sv)
RU (1) RU2128173C1 (sv)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0573218B1 (en) * 1992-06-02 2001-03-07 Sankyo Company Limited 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use
CA2111662C (en) * 1992-12-17 2004-11-23 Hiroaki Yanagisawa Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
HUT74734A (en) * 1994-03-16 1997-02-28 Sankyo Co Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
CZ299162B6 (cs) * 1996-07-15 2008-05-07 Sankyo Company, Limited Farmaceutický prípravek a souprava
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
AU5566400A (en) * 1999-06-22 2001-01-09 Takeda Chemical Industries Ltd. Process for the preparation of imidazole derivatives
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
SK5992003A3 (en) * 2000-11-21 2003-11-04 Sankyo Co Medicinal composition comprising an angiotensin II receptor antagonist and one or more diuretics and use thereof
NZ531346A (en) * 2001-08-28 2005-10-28 Sankyo Co Medicinal compositions containing angiotensin II receptor antagonist
EP1604664A4 (en) 2003-01-31 2006-12-27 Sankyo Co MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
KR101087519B1 (ko) * 2003-04-15 2011-11-28 상꾜 가부시키가이샤 안구 내 혈관 신생성 질환의 예방 또는 치료를 위한 의약
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1713795A2 (en) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
TW200605867A (en) 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
CN1976926A (zh) * 2004-09-02 2007-06-06 特瓦制药工业有限公司 奥美沙坦酯的制备
US20080085914A1 (en) 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
BRPI0518229A (pt) 2004-10-27 2008-11-04 Daiichi Sankyo Co Ltd composto de benzeno tendo 2 ou mais substituintes
EP1716138A1 (en) * 2004-12-30 2006-11-02 Teva Pharmaceutical Industries Ltd Process for preparing olmesartan medoxomil at ph higher than 2.5
CN101094850A (zh) * 2005-01-03 2007-12-26 特瓦制药工业有限公司 具有较低水平杂质的奥美沙坦酯
DE602006010364D1 (de) * 2005-04-22 2009-12-24 Daiichi Sankyo Co Ltd Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
EP1816131A1 (en) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of olmesartan medoxomil
EA014026B1 (ru) * 2005-07-29 2010-08-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения олмесартан медоксомила
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (en) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
JP5047156B2 (ja) * 2006-02-27 2012-10-10 武田薬品工業株式会社 医薬パッケージ
SI1891952T1 (sl) 2006-05-04 2012-02-29 Lek Pharmaceuticals, D.D. Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
US8048904B2 (en) * 2006-06-19 2011-11-01 Matrix Laboratories Ltd. Process for the preparation of olmesartan medoxomil
US8242151B2 (en) 2007-02-07 2012-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
JPWO2008117707A1 (ja) * 2007-03-23 2010-07-15 第一三共株式会社 オルメサルタンメドキソミルの粉砕結晶
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
US20100130567A1 (en) * 2007-06-22 2010-05-27 Daiichi Sankyo Company, Limited Medical agent for prevention or treatment of alzheimer 's disease
HUE025230T2 (en) * 2008-06-09 2016-02-29 Daiichi Sankyo Co Ltd Process for the preparation of 1-biphenylmethylimidazole compound
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
EP2374799B1 (en) 2008-11-17 2013-05-22 Shanghai Institute of Pharmaceutical Industry Process for the preparation of 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylates
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8859600B2 (en) 2009-04-28 2014-10-14 Daiichi Sankyo Company, Limited Acetone solvate crystals of trityl olmesartan medoxomil
KR101676512B1 (ko) 2009-04-28 2016-11-15 다이이찌 산쿄 가부시키가이샤 올메살탄메독소밀의 제조 방법
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
WO2011083112A2 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP6086865B2 (ja) 2011-08-03 2017-03-01 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN104583185A (zh) 2012-08-31 2015-04-29 株式会社Api 联芳基化合物的制造方法
EP2902385B1 (en) 2012-09-26 2019-01-09 API Corporation Deprotection method for tetrazole compound
WO2014054798A1 (ja) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
KR20180123021A (ko) 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 신질환의 치료를 위한 의약
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0515548A4 (en) 1990-02-13 1993-03-10 Merck & Co. Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
NO954507D0 (no) 1995-11-09
IL114996A0 (en) 1995-12-08
CA2061607A1 (en) 1992-08-22
NO920688L (no) 1992-08-24
NL300133I1 (nl) 2003-10-01
HU9200578D0 (en) 1992-05-28
NO304516B3 (no) 2012-06-11
CZ289194B6 (cs) 2001-11-14
NO304517B1 (no) 1999-01-04
CN1189490A (zh) 1998-08-05
GR3035906T3 (en) 2001-08-31
FI955248A0 (sv) 1995-11-02
CN1065063A (zh) 1992-10-07
DE69231801D1 (de) 2001-05-31
DE69231801T2 (de) 2001-12-06
NO304516B1 (no) 1999-01-04
JPH07121918B2 (ja) 1995-12-25
FI112941B (sv) 2004-02-13
NO920688D0 (no) 1992-02-21
HUT60475A (en) 1992-09-28
GR3035909T3 (en) 2001-08-31
CA2229000C (en) 2002-04-09
RU2128173C1 (ru) 1999-03-27
RU95101430A (ru) 1997-02-20
CN1101384C (zh) 2003-02-12
NO2003009I2 (en) 2007-12-11
EP0545912B1 (en) 2001-04-25
EP0545912A3 (en) 1993-06-16
AU647887B2 (en) 1994-03-31
IE920540A1 (en) 1992-08-26
HU211934A9 (en) 1996-01-29
DE122009000024I1 (de) 2009-09-17
DE69231798T2 (de) 2001-12-06
LU91330I2 (fr) 2007-06-04
PT503785E (pt) 2001-08-30
IS1756B (is) 2000-12-28
CA2061607C (en) 1999-01-19
NO2011013I1 (no) 2011-08-22
ATE200778T1 (de) 2001-05-15
NO954507L (no) 1992-08-24
IL101034A0 (en) 1992-11-15
DE122011000011I1 (de) 2011-06-16
DK0503785T3 (da) 2001-06-18
HK1011969A1 (en) 1999-07-23
FI955248A (sv) 1995-11-02
ES2157895T3 (es) 2001-09-01
NL300375I1 (nl) 2009-04-01
HU9601179D0 (en) 1996-07-29
EP0503785B1 (en) 2001-04-25
DE69231798T3 (de) 2012-07-12
NL300227I1 (nl) 2006-06-01
DE69231798D1 (de) 2001-05-31
KR920016429A (ko) 1992-09-24
CZ51692A3 (en) 1993-03-17
CN1045770C (zh) 1999-10-20
NL300133I2 (nl) 2004-03-01
NO2009019I1 (no) 2009-09-21
DK0545912T3 (da) 2001-06-18
EP0545912A2 (en) 1993-06-09
HU223338B1 (hu) 2004-06-28
ES2156866T3 (es) 2001-08-01
IS3819A (is) 1992-08-22
KR0128289B1 (ko) 1998-04-02
LU91847I2 (fr) 2011-09-26
AU1112592A (en) 1992-08-27
ES2157895T7 (es) 2012-06-14
ATE200777T1 (de) 2001-05-15
LU91056I2 (fr) 2004-10-19
DE10299043I1 (de) 2003-03-27
FI112942B3 (sv) 2012-03-13
PT545912E (pt) 2001-08-30
CA2229000A1 (en) 1992-08-22
FI920749A (fi) 1992-08-22
JPH0578328A (ja) 1993-03-30
IE970752A1 (en) 2000-02-23
CN1121859C (zh) 2003-09-24
LU91571I2 (fr) 2009-07-13
HK1011361A1 (en) 1999-07-09
EP0503785B3 (en) 2012-02-29
FI920749A0 (fi) 1992-02-20
DE10299043I2 (de) 2003-08-07
NO2006012I1 (no) 2006-10-30
CN1188645A (zh) 1998-07-29
DE122005000051I1 (de) 2006-01-26
IL101034A (en) 1996-10-16
EP0503785A1 (en) 1992-09-16
IL114996A (en) 1997-07-13
NZ241681A (en) 1993-07-27
HU223667B1 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
FI112942B (sv) Förfarande för framställning av för behandling och förebyggande av höjt blodtryck användbara 4'-(1H-imidazol-1-ylmetyl)-1,1'-bifenyl-derivat
IE83299B1 (en) 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use
CN101657424B (zh) 双重作用的抗高血压药剂
FI108434B (sv) F÷rfarande f÷r framstõllning av farmakologiskt verksamma bensimidazolderivat
US5616599A (en) Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
JP4991711B2 (ja) 不飽和または環状リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用
JP3120075B2 (ja) 化合物
US20120095047A1 (en) Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors
ZA200605526B (en) Substituted azole derivatives, compositions and methods of use
AU2006261845A1 (en) Imidazole based LXR modulators
KR100275604B1 (ko) 치환된 사이클로헥산 유도체,이의 제조방법 및 이를 함유하는 약제학적 조성물
EP0565396A1 (fr) Dérivés de 1-(2-(arylsulfonylamino)-1-oxoéthyl)pipéridine, leur préparation et leur application en thérapeutique
JP2013517295A (ja) 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬
RU2174513C2 (ru) Четырехзамещенные производные имидазола, способы их получения, промежуточные соединения и фармацевтическая композиция
EP0620813A1 (en) Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin ii
EP0644188B1 (fr) Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus
RU2092481C1 (ru) Производные 1-бифенилметилимидазола, их фармацевтически приемлемые соли или эфиры и способ их получения
CZ289244B6 (cs) 1-Bifenylmethylimidazolové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
IE83343B1 (en) 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040002

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060012

PC Transfer of assignment of patent

Owner name: DAIICHI SANKYO COMPANY LIMITED

Free format text: DAIICHI SANKYO COMPANY LIMITED

SPCG Supplementary protection certificate granted
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: C20110023

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 328

Extension date: 20170220

MA Patent expired